Legislative Overhaul 'Will Not Make EU A Global Leader' In Pharma R&D
Industry Says 'Flexible And Coherent’ Regulatory System Needed
National pricing and reimbursement systems remain a key barrier to medicines access, and requiring companies to market their products in all EU countries and to notify regulators of their launch intentions is not the answer, according to EuropaBio, which represents a wide range of biotech firms operating in Europe.
